Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sulkowski

Showing results (1-10 of 408) with videos related to

Pageof 41
Sort By:
Roczniki Akademii Medycznej W Bialymstoku (1995)|February 11, 1999
Type II alveolar epithelial cells and cyclophosphamide-induced lung fibrosisS Sulkowski
Roczniki Akademii Medycznej W Bialymstoku (1995)|February 11, 1999
The effect of cyclophosphamide on the ultrastructure of erythrocytesS Sulkowski
Liver International : Official Journal of the International Association for the Study of the Liver|January 4, 2012
Hepatitis C virus-human immunodeficiency virus coinfectionMark S Sulkowski
Journal of Hepatology|December 25, 2007
Viral hepatitis and HIV coinfectionMark S Sulkowski
Clinical Liver Disease|June 13, 2019
Hepatitis C genotype 1 infection in HIV-Infected patients in the era of direct-acting antiviral therapyMark S Sulkowski
Journal of Hepatology|December 3, 2014
Management of acute and chronic HCV infection in persons with HIV coinfectionMark S Sulkowski
The Hopkins HIV Report : a Bimonthly Newsletter for Healthcare Providers|December 1, 2001
Is there a point at which you would recommend discontinuing treatment due to liver toxicity, short of liver failure? What, for instance, would be the numbers to look for with liver enzyme tests? How high is too high? My doctor has said they are seeing more people in their practice die from liver disorders than from the virus itself nowadays. This has me very concerned since I am co-infected with HCVM S Sulkowski
The Hopkins HIV Report : a Bimonthly Newsletter for Healthcare Providers|August 20, 2002
Hepatitis C coinfection gains a foothold at the 8th CROIM S Sulkowski
Seminars in Liver Disease|June 12, 2003
Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitorsMark S Sulkowski
Seminars in Liver Disease|May 1, 2014
Interferon-containing and interferon-free HCV therapy for HIV-infected patientsMark S Sulkowski
Pageof 41

Showing results (1-10 of 408) with videos related to

Sort By:
Pageof 41
Roczniki Akademii Medycznej W Bialymstoku (1995)|February 11, 1999
Type II alveolar epithelial cells and cyclophosphamide-induced lung fibrosisS Sulkowski
Roczniki Akademii Medycznej W Bialymstoku (1995)|February 11, 1999
The effect of cyclophosphamide on the ultrastructure of erythrocytesS Sulkowski
Liver International : Official Journal of the International Association for the Study of the Liver|January 4, 2012
Hepatitis C virus-human immunodeficiency virus coinfectionMark S Sulkowski
Journal of Hepatology|December 25, 2007
Viral hepatitis and HIV coinfectionMark S Sulkowski
Clinical Liver Disease|June 13, 2019
Hepatitis C genotype 1 infection in HIV-Infected patients in the era of direct-acting antiviral therapyMark S Sulkowski
Journal of Hepatology|December 3, 2014
Management of acute and chronic HCV infection in persons with HIV coinfectionMark S Sulkowski
The Hopkins HIV Report : a Bimonthly Newsletter for Healthcare Providers|December 1, 2001
Is there a point at which you would recommend discontinuing treatment due to liver toxicity, short of liver failure? What, for instance, would be the numbers to look for with liver enzyme tests? How high is too high? My doctor has said they are seeing more people in their practice die from liver disorders than from the virus itself nowadays. This has me very concerned since I am co-infected with HCVM S Sulkowski
The Hopkins HIV Report : a Bimonthly Newsletter for Healthcare Providers|August 20, 2002
Hepatitis C coinfection gains a foothold at the 8th CROIM S Sulkowski
Seminars in Liver Disease|June 12, 2003
Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitorsMark S Sulkowski
Seminars in Liver Disease|May 1, 2014
Interferon-containing and interferon-free HCV therapy for HIV-infected patientsMark S Sulkowski
Pageof 41